The burden of progressive fibrotic interstitial lung disease across the UK

Thomas Simpson; Shaney L Barratt; Paul Beirne; Nazia Chaudhuri; Anjali Crawshaw; Louise E Crowley; Sophie Fletcher; Michael A Gibbons; Philippa Hallchurch; Laura Horgan; Ieva Jakaityte; Thomas Lewis; Tom McLellan; Katherine J Myall; Ryan Miller; David J F Smith; Stefan Stanel; Muhunthan Thillai; Fiona Thompson; Timothy Wallis; Zhe Wu; Philip L Molyneaux; Alex G West

doi:10.1183/13993003.00221-2021

The burden of progressive fibrotic interstitial lung disease across the UK

Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021. Print 2021 Jul.

Authors

Thomas Simpson¹, Shaney L Barratt^{2

3}, Paul Beirne⁴, Nazia Chaudhuri⁵, Anjali Crawshaw⁶, Louise E Crowley⁶, Sophie Fletcher⁷, Michael A Gibbons⁸, Philippa Hallchurch², Laura Horgan⁴, Ieva Jakaityte⁸, Thomas Lewis², Tom McLellan⁹, Katherine J Myall¹, Ryan Miller⁸, David J F Smith¹⁰, Stefan Stanel⁵, Muhunthan Thillai⁹, Fiona Thompson⁷, Timothy Wallis⁷, Zhe Wu^{10

11}, Philip L Molyneaux^{10

11

12}, Alex G West^{1

12}

Affiliations

¹ Dept of Respiratory Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
² Bristol Interstitial Lung Disease Service, North Bristol NHS trust, Southmead Hospital, Bristol, UK.
³ Academic Respiratory Unit, University of Bristol, Bristol, UK.
⁴ Leeds Interstitial Lung Disease Service, St James's University Hospital, Leeds, UK.
⁵ North West Lung Centre, Wythenshawe Hospital, Manchester, UK.
⁶ Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁷ University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
⁸ South West Peninsula ILD Network, Royal Devon and Exeter Foundation NHS Trust, Exeter, UK.
⁹ Dept of Interstitial Lung Disease, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
¹⁰ Royal Brompton Hospital, London, UK.
¹¹ National Heart and Lung Institute, Imperial College London, London, UK.
¹² Contributed equally as last authors.

Abstract

Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lung
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / epidemiology
Pulmonary Fibrosis* / epidemiology
United Kingdom / epidemiology